GetTopicDetailResponse(id=aa8d252611, topicName=ANGPTL3, introduction=ANGPTL3, content=null, image=null, comments=2, allHits=1531, url=https://h5.medsci.cn/topic?id=2526, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=51220, tagList=[TagDto(tagId=51220, tagName=ANGPTL3)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1247615, encodeId=7fba124e6154c, content=<a href='/topic/show?id=aa8d252611' target=_blank style='color:#2F92EE;'>#ANGPTL3#</a>這個<a href='/topic/show?id=07a69996557' target=_blank style='color:#2F92EE;'>#靶點#</a>終于開始成藥了，它能把<a href='/topic/show?id=593c10e5975' target=_blank style='color:#2F92EE;'>#LDL-C#</a> 降到比<a href='/topic/show?id=c5d9138e8eb' target=_blank style='color:#2F92EE;'>#PCSK9i#</a>更低的水平, objectTitle=NEJM：ANGPTL3與冠心病風(fēng)險, objectType=article, longId=100010, objectId=16b7100010c7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201705/20170528120310986.jpg, objectUrl=/article/show_article.do?id=16b7100010c7, replyNumber=0, likeNumber=175, createdTime=2022-09-07, rootId=0, userName=小小醫(yī)者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16b7100010c7, moduleTitle=NEJM：ANGPTL3與冠心病風(fēng)險, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=16b7100010c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1247616, encodeId=4a78124e616d2, content=<a href='/topic/show?id=aa8d252611' target=_blank style='color:#2F92EE;'>#ANGPTL3#</a>單抗<a href='/topic/show?id=374ce12041' target=_blank style='color:#2F92EE;'>#Evinacumab#</a>治療<a href='/topic/show?id=23814643930' target=_blank style='color:#2F92EE;'>#家族性高膽固醇血癥#</a>的III期臨床成功，未來有望成為常規(guī)<a href='/topic/show?id=3323981903c' target=_blank style='color:#2F92EE;'>#降脂#</a>的藥物, objectTitle=Regeneron的ANGPTL3單抗evinacumab治療家族性高膽固醇血癥的III期臨床成功, objectType=article, longId=177716, objectId=cb201e7716eb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201908/20190815110335613.jpg, objectUrl=/article/show_article.do?id=cb201e7716eb, replyNumber=0, likeNumber=168, createdTime=2022-09-07, rootId=0, userName=小小醫(yī)者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb201e7716eb, moduleTitle=Regeneron的ANGPTL3單抗evinacumab治療家族性高膽固醇血癥的III期臨床成功, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=cb201e7716eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
